Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder mediated by autoantibodies that target functionally vital proteins in the post-synaptic membrane at the neuromuscular junction (NMJ).1 MG presents clinically with a fluctuating degree and variable combination of motor weakness in the ocular, bulbar, limb, and respiratory muscles. The detection of antibodies plays a central role in confirming MG diagnosis, defining subgroups, and guiding the management of MG patients
Myasthenia Gravis Autoantibody Profile